These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 20332761)

  • 1. Ultrastructural changes in tumor cells treated with liposomal forms of anticancer drugs.
    Yurchenko OV; Rusetskya NV; Naleskina LA; Chekhun VF
    Exp Oncol; 2010 Mar; 32(1):23-8. PubMed ID: 20332761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin.
    Rusetskaya NV; Lukyanova NY; Chekhun VF
    Exp Oncol; 2009 Sep; 31(3):140-3. PubMed ID: 19783968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin.
    Lukyanova NY; Rusetskya NV; Tregubova NA; Chekhun VF
    Exp Oncol; 2009 Jun; 31(2):87-91. PubMed ID: 19550397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of homocysteine-induced multidrug resistance of human MCF-7 breast cancer cells and human A2780 ovarian cancer cells.
    Lukyanova NY
    Exp Oncol; 2010 Mar; 32(1):10-4. PubMed ID: 20332764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
    Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of anticancer drugs on production of transforming growth factor and expression of p53 AND Bcl-2 proteins by MCF-7 and T47D cell lines of human breast carcinoma.
    Stoika RS; Yakymovych IA; Kashchak NI; Boyko MM; Korynevska AV; Klyuchyvska OY; Shafranska GI; Yakymovych MY; Zhylchuk VY; Kudryavets YY; Vorontsova AL
    Exp Oncol; 2008 Mar; 30(1):35-41. PubMed ID: 18438339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12.
    Thomadaki H; Scorilas A
    Ann N Y Acad Sci; 2007 Jan; 1095():35-44. PubMed ID: 17404015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines.
    Kars MD; Işeri OD; Gunduz U; Molnar J
    Chemotherapy; 2008; 54(3):194-200. PubMed ID: 18560226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.
    Licht T; Lübbert M; Martens C; Bross KJ; Fiebig HH; Mertelsmann R; Herrmann F
    Cytokines Mol Ther; 1995 Jun; 1(2):123-32. PubMed ID: 9384669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
    Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
    J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin.
    Weinstein-Oppenheimer CR; Henríquez-Roldán CF; Davis JM; Navolanic PM; Saleh OA; Steelman LS; Franklin RA; Robinson PJ; McMahon M; McCubrey JA
    Clin Cancer Res; 2001 Sep; 7(9):2898-907. PubMed ID: 11555608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
    Xu H; Choi SM; An CS; Min YD; Kim KC; Kim KJ; Choi CH
    Biochem Biophys Res Commun; 2005 Mar; 328(2):618-22. PubMed ID: 15694393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2004 Dr. Gary J. Becker Young Investigator Award: Relative thermosensitivity of cytotoxic drugs used in transcatheter arterial chemoembolization.
    Ahrar K; Newman RA; Pang J; Vijjeswarapu MK; Wallace MJ; Wright KC
    J Vasc Interv Radiol; 2004 Sep; 15(9):901-5. PubMed ID: 15361556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells.
    Kopecka J; Campia I; Olivero P; Pescarmona G; Ghigo D; Bosia A; Riganti C
    J Control Release; 2011 Jan; 149(2):196-205. PubMed ID: 20946921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill.
    Schenk PW; Brok M; Boersma AW; Brandsma JA; Den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K
    Mol Pharmacol; 2003 Aug; 64(2):259-68. PubMed ID: 12869630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs.
    Fromigué O; Hamidouche Z; Marie PJ
    J Pharmacol Exp Ther; 2008 May; 325(2):595-600. PubMed ID: 18252811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
    Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.